Clarity Pharmaceuticals Ltd.

As of June 30, 2025, Clarity Pharmaceuticals Ltd. carries a market capitalization of 803.68M, placing it among publicly traded companies globally. Its enterprise value stands at 719.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Clarity Pharmaceuticals Ltd.'s next confirmed earnings release is scheduled for March 4, 2027.

As of June 30, 2025, Clarity Pharmaceuticals Ltd. has 321.47M shares outstanding.

These figures are as of June 30, 2025.

As of June 30, 2025, Clarity Pharmaceuticals Ltd. maintains a current ratio of 9.69, meaning it holds 9.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2025, Clarity Pharmaceuticals Ltd. posted a negative return on equity (ROE) of -54.37, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -50.27, reflecting losses generated across the asset base.

Over the twelve months ended June 30, 2025, Clarity Pharmaceuticals Ltd. recorded 416,506.00 in income tax expense. The company reported a pretax loss of -63.88M and -64.30M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Clarity Pharmaceuticals Ltd.'s stock has declined approximately 65.10% over the past 52 weeks. The 50-day moving average sits at 2.17, while the 200-day moving average is 2.70.

These figures cover the twelve months ended June 30, 2025. EBITDA reached -78.37M, while operating income came in at -78.56M.

These figures are as of June 30, 2025. Total book value stands at 90.23M, with working capital of 90.23M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -0.28, meaning Clarity Pharmaceuticals Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Clarity Pharmaceuticals Ltd.'s most recent stock split took place on March 28, 2024 with a 1000:1003 split ratio.